SGC001 clinical trials
Also written SGC001.
How each study uses SGC001 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SGC001 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Beijing Sungen Biomedical Technology Co., Ltd (4)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test SGC001.
- Apr 2027A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial InfarctionPhase 2 · Beijing Sungen Biomedical Technology Co., Ltd
- Nov 2027Study of SGC001 Injection for Predicted Severe Acute Pancreatitis to Assess Safety, Tolerability and Preliminary EfficacyPhase 2 · Beijing Sungen Biomedical Technology Co., Ltd
Studies
Open first, then newest update. How each study uses SGC001 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Study of SGC001 Injection for Predicted Severe Acute Pancreatitis to Assess Safety, Tolerability and Preliminary EfficacyRecruitingPhase 2Beijing Sungen Biomedical Technology Co., LtdNCT07803965Written as SGC001 injection
- A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial InfarctionRecruitingPhase 2Beijing Sungen Biomedical Technology Co., LtdNCT07306182Written as SGC001 injection
- A Research Study to Evaluate the Safety and Preliminary Efficacy of SGC001 in Patients With Myocardial InfarctionCompletedPhase 1Beijing Sungen Biomedical Technology Co., LtdNCT07091929Written as SGC001
- A Research Study to Evaluate the Safety and Tolerability of SGC001 in Healthy SubjectsCompletedPhase 1Beijing Sungen Biomedical Technology Co., LtdNCT07079618Written as SGC001